Last Updated on November 11, 2025 by The Health Master
Drug recall
Recently, Zydus Pharmaceuticals Inc., the U.S. branch of Zydus Lifesciences, initiated a significant voluntary drug recall of its Entecavir tablets.
This essential antiviral medication, used to treat chronic Hepatitis B virus (HBV) infection, is being pulled from shelves because the product failed to meet specific “impurities/degradation specifications.”
In simple terms, the medicine wasn’t stable enough and developed unwanted substances as it broke down.
The drug recall involves two separate batches manufactured at the company’s facility in Ahmedabad, India, adding up to over 1,500 bottles.
Specifically, 912 bottles of the 0.5 mg Entecavir strength and 600 bottles of the 1 mg Entecavir strength were included in the action, which began on September 24, 2025.
This quality failure is a serious matter, highlighting the need for vigilance in drug manufacturing processes globally.
Understanding the Issue
The core of the problem stems from the tablets’ stability, specifically the Entecavir recall was triggered due to a failure to meet impurity and degradation specifications.
When a medicine degrades, its active ingredient can become less effective, and the degradation products (the impurities) can sometimes pose health risks.
This voluntary action has been officially categorized by the U.S. Food and Drug Administration (USFDA) as a Class II Drug Recall.
Class II drug recall
A Class II drug recall classification indicates that, while the product may cause temporary or medically reversible adverse health consequences, the probability of serious adverse health consequences is considered remote.
This means while the quality issue is real, the immediate, severe danger to patients is low.
However, patients relying on this drug for long-term management of Hepatitis B need a product they can trust.
Recent Drug Recalls
It’s notable that this is not the first instance of this particular issue.
Last month, Zydus had already initiated two similar voluntary drug recalls for approximately 8,700 bottles of the identical drug, citing the very same Zydus Entecavir quality issue.
The recurring nature of this problem indicates a potentially deeper systemic challenge in the manufacturing or quality control process that requires urgent attention.
Q: What should patients do if they have Hepatitis B Drug tablets?
A: Patients should not stop taking their medication immediately. They should contact their pharmacist or doctor right away to check if their prescription is from the affected lot and to secure a replacement.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Disclaimer: The information we have provided is for general knowledge and for informational purpose only and it cannot be treated as medical advice. Always consult your doctor for any health issues and / or for the treatment of the same. The Health Master does not claim responsibility for this information.
Drug recall: 5 Indian Companies recall drugs over quality issues
Drug recall: Unichem recalls Cyclobenzaprine HCL Tablets
Drug recall: Cipla recalls 20,352 packs of this Asthma drug
Drug recall: Glenmark recalls High BP, COPD drug
Drug recall: Alembic recalls 9,492 bottles of Doxepin Capsules
Govt rolls out incentive scheme for Pharma and MedTech sector
USFDA approval granted for Paroxetine Extended-Release tablets: Alembic
Drug recall: 5 Indian Companies recall drugs over quality issues
India Bans 34 Key Antimicrobials for Animal Use
49 new Drug Inspectors join in CDSCO
USFDA Inspection: At Jubilant with Zero observations
USFDA issued Form 483 to Lupin with 4 observations: Pune
Drug alert: 94 drug samples declared as NSQ in August 2025
USFDA issued Form 483 to Lupin with 6 observations: Nagpur
Haryana: ₹5,000 Crore investment Plan for Pharma and Medical Device
